Patents by Inventor Jamie Iain Campbell
Jamie Iain Campbell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11858996Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.Type: GrantFiled: August 9, 2017Date of Patent: January 2, 2024Assignee: KYMAB LIMITEDInventors: Richard Charles Alfred Sainson, Stephen John Arkinstall, Jamie Iain Campbell, Mohammed Hanif Ali, E-Chiang Lee, Matthew John McCourt, Volker Germaschewski, Ian Kirby, Miha Kosmac, Nahida Parveen, Robert Rowlands, Gwenoline Borhis
-
Publication number: 20230348601Abstract: Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.Type: ApplicationFiled: February 27, 2023Publication date: November 2, 2023Inventors: Matthew John MCCOURT, Richard Charles Alfred SAINSON, Jamie Iain CAMPBELL, Stephen John ARKINSTALL, Mihriban TUNA, Ryan FIEHLER, Mustapha FAROUDI, Fadi BADR, Francisca WOLLERTON VAN HORCK, Frederick AKELE
-
Patent number: 11629189Abstract: Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.Type: GrantFiled: December 19, 2018Date of Patent: April 18, 2023Assignee: KYMAB LIMITEDInventors: Matthew John McCourt, Richard Charles Alfred Sainson, Jamie Iain Campbell, Stephen John Arkinstall, Mihriban Tuna, Ryan Fiehler, Mustapha Faroudi, Fadi Badr, Francisca Wollerton Van Horck, Frederick Akele
-
Publication number: 20220403029Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.Type: ApplicationFiled: April 22, 2022Publication date: December 22, 2022Inventors: Richard Charles Alfred SAINSON, Stephen John ARKINSTALL, Jamie Iain CAMPBELL, Mohammed Hanif ALI, E-Chiang LEE, Matthew John MCCOURT, Nikole SANDY, Cassandra VAN KRINKS, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
-
Publication number: 20220380467Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.Type: ApplicationFiled: April 22, 2022Publication date: December 1, 2022Inventors: Richard Charles Alfred SAINSON, Stephen John ARKINSTALL, Jamie Iain CAMPBELL, Mohammed Hanif ALI, E-Chiang LEE, Matthew John MCCOURT, Nikole SANDY, Cassandra VAN KRINKS, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
-
Publication number: 20200407446Abstract: Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.Type: ApplicationFiled: December 19, 2018Publication date: December 31, 2020Inventors: Matthew John MCCOURT, Richard Charles Alfred SAINSON, Jamie Iain CAMPBELL, Stephen John ARKINSTALL, Mihriban TUNA, Ryan FIEHLER, Mustapha FAROUDI, Fadi BADR, Francisca WOLLERTON VAN HORCK, Frederik AKELE
-
Publication number: 20200190191Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.Type: ApplicationFiled: December 19, 2017Publication date: June 18, 2020Inventors: Jamie Iain CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
-
Publication number: 20190330345Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.Type: ApplicationFiled: August 9, 2017Publication date: October 31, 2019Inventors: Richard Charles Alfred SAINSON, Stephen John ARKINSTALL, Jamie Iain CAMPBELL, Mohammed Hanif ALI, E-Chiang LEE, Matthew John MCCOURT, Nikole SANDY, Cassandra VAN KRINKS, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
-
Patent number: 10259880Abstract: The present invention relates to anti-human LIGHT antibodies, new medical uses and methods.Type: GrantFiled: January 13, 2015Date of Patent: April 16, 2019Assignee: KYMAB LIMITEDInventors: Jamie Iain Campbell, Bettina Franz, Steve Holmes, Ian Kirby, Anais Legent
-
Patent number: 9957323Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.Type: GrantFiled: September 7, 2017Date of Patent: May 1, 2018Assignee: Kymab LimitedInventors: Richard Charles Alfred Sainson, Stephen John Arkinstall, Jamie Iain Campbell, Mohammed Hanif Ali, E-Chiang Lee, Matthew John McCourt, Nikole Sandy, Cassandra Van Krinks, Volker Germaschewski, Ian Kirby, Miha Kosmac, Thomas Gallagher, Cecilia Deantonio, Stephen D. Gillies
-
Publication number: 20180066058Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.Type: ApplicationFiled: September 7, 2017Publication date: March 8, 2018Inventors: Richard Charles Alfred SAINSON, Stephen John ARKINSTALL, Jamie Iain CAMPBELL, Mohammed Hanif ALI, E-Chiang LEE, Matthew John MCCOURT, Nikole SANDY, Cassandra VAN KRINKS, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen D. GILLIES
-
Publication number: 20170320956Abstract: The present invention relates to anti-human LIGHT antibodies, new medical uses and methods.Type: ApplicationFiled: June 16, 2017Publication date: November 9, 2017Applicant: KYMAB LIMITEDInventors: Jamie Iain CAMPBELL, Bettina FRANZ, Steve HOLMES, Ian KIRBY, Anais LEGENT
-
Publication number: 20170291951Abstract: The present invention relates to anti-human LIGHT antibodies, new medical uses and methods.Type: ApplicationFiled: January 13, 2015Publication date: October 12, 2017Applicant: KYMAB LIMITEDInventors: Jamie Iain CAMPBELL, Bettina FRANZ, Steve HOLMES, Ian KIRBY, Anais LEGENT
-
Publication number: 20160096895Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: October 23, 2015Publication date: April 7, 2016Inventors: JAMIE IAIN CAMPBELL, DUNCAN JAMES COCHRANE, DONNA KIRSTY FINCH, MARIA ANASTASIA TERESA GROVES, DAVID CHRISTOPHER LOWE, SIMON CHARLES CRUWYS
-
Patent number: 9200074Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD).Type: GrantFiled: April 16, 2014Date of Patent: December 1, 2015Assignee: MEDIMMUNE LIMITEDInventors: Jamie Iain Campbell, Duncan James Cochrane, Donna Kirsty Finch, Maria Anastasia Teresa Groves, David Christopher Lowe, Simon Charles Cruwys
-
Publication number: 20140212429Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: April 16, 2014Publication date: July 31, 2014Applicant: MEDIMMUNE LIMITEDInventors: JAMIE IAIN CAMPBELL, DUNCAN JAMES COCHRANE, DONNA KIRSTY FINCH, MARIA ANASTASIA TERESA GROVES, DAVID CHRISTOPHER LOWE, SIMON CHARLES CRUWYS
-
Patent number: 8741604Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD).Type: GrantFiled: September 14, 2012Date of Patent: June 3, 2014Assignee: Medimmune LimitedInventors: Jamie Iain Campbell, Duncan James Cochrane, Donna Kirsty Finch, Maria Anastasia Teresa Groves, David Christopher Lowe, Simon Charles Cruwys
-
Publication number: 20130078717Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, athma and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: September 14, 2012Publication date: March 28, 2013Applicant: MedImmune LimitedInventors: Jamie Iain CAMPBELL, Duncan James Cochrane, Donna Kirsty Finch, Maria Anastasia Teresa Groves, David Christopher Lowe, Simon Charles Cruwys
-
Patent number: 8298533Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, asthma and chronic obstructive pulmonary disease (COPD).Type: GrantFiled: November 5, 2009Date of Patent: October 30, 2012Assignee: MedImmune LimitedInventors: Jamie Iain Campbell, Duncan James Cochrane, Donna Kirsty Finch, Maria Anastasia Teresa Groves, David Christopher Lowe, Simon Charles Cruwys
-
Publication number: 20100221257Abstract: This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The binding members are useful for, inter alia, treatment of disorders mediated by IL-1R1 including rheumatoid arthritis, athma and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: November 5, 2009Publication date: September 2, 2010Applicant: MEDIMMUNE LIMITEDInventors: Jamie Iain Campbell, Duncan James Cochrane, Donna Kirsty Finch, Maria Anastasia Teresa Groves, David Christopher Lowe, Simon Charles Cruwys
